NASDAQ : ABVX

ABIVAX Société Anonyme — Company profile

Healthcare · Biotechnology · France

Last price 86.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.69B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Details

NameABIVAX Société Anonyme
SectorHealthcare
IndustryBiotechnology
Employees98
Founded2013
CeoMarc M. de Garidel
CountryFrance
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
Ipo Price11.60
IsinUS00370M1036
Cusip00370M103
Cik1956827
Sic2834

Key executives

NameTitle
Marc M. P. de Garidel M.B.A.Chief Executive Officer and Director
Didier BlondelEVice President, Chief Financial Officer and Board Secretary
Timothy P. Kelly M.B.A.Chief Technical Officer
Patrick MalloySenior Vice President and Head of Investor Relations
Ida HatoumChief People and Compliance Officer
James BergerGlobal Head of Marketing
Pierre Courteille M.B.A.Chief Business Officer

Contact

Address7-11 Boulevard Haussmann, Paris, 75009, France
Phone33 1 53 83 09 63
Websitehttps://www.abivax.com